Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study

Tingting Gao\textsuperscript{1} · Jinfeng Qu\textsuperscript{1} · Jing Xiao\textsuperscript{2} · Jie Hu\textsuperscript{1} · Mingwei Zhao\textsuperscript{1}

Abstract

Purpose To evaluate the efficacy of half-dose photodynamic therapy (PDT) for the treatment of bullous retinal detachment.

Methods Interventional prospective case series in six eyes from six consecutive patients with bullous retinal detachment. The affected eyes were treated with indocyanine green angiography (ICGA)-guided half-dose PDT with multifocal and large laser spots. Clinical evaluations included best-corrected visual acuity (BCVA), ophthalmoscopy, ophthalmic B scan, fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and ICGA at each scheduled visit at baseline; at 1, 3, and 6 months after PDT; and during follow-up after 6 months.

Results All six eyes received half-dose verteporfin PDT with a mean number of therapeutic spots 2.83 ± 1.47 and a mean spot size of 4647 ± 996 μm in diameter. Three months after PDT, retinal reattachment was observed on B scans and resolution of sub-retinal fluid (SRF) was observed in OCT images for five eyes. There was no significant difference in the mean logMAR BCVA between the baseline and the value at 1 month after PDT ($P=0.477$). At 3 months after PDT, the mean logMAR BCVA improved significantly from a baseline value of 1.02 to 0.54 ($P=0.044$). At 6 months after PDT, the mean logMAR BCVA further improved to 0.46 ($P=0.025$) and remained stable. One affected eye received a second half-dose PDT for SRF not reduced until the second month after PDT. Retinal reattachment and SRF resolution were observed at 1 and 3 months after the second therapy, respectively. BCVA improved from a baseline value of 20/63 to 20/20 at 1 month after the second PDT and remained stable until the sixth month after the second PDT. During follow-up after more than 6 months, recurrence occurred in no cases.

Conclusions This study demonstrated half-dose PDT with multifocal and large laser spots was an effective treatment for bullous retinal detachment contributing to the retinal reattachment, a resolution of SRF, and an improvement of BCVA. Thus, PDT for the treatment of bullous retinal detachment is considered to be a worthwhile endeavor.

Keywords Bullous retinal detachment · Efficacy · Photodynamic therapy · Multifocal · Large laser spot

Introduction

Chronic central serous chorioretinopathy (CSC) is a major threat to central vision in the working population and is mainly characterized by the serous detachment of the neurosensory layer of the retina from the retinal pigment epithelium in the macular area [1, 2]. The detachment spontaneously resolves within 2 to 3 months in two-thirds of affected individuals, which is defined as acute CSC [3]. However, more than one-third of patients experience chronic forms of CSC with persistent sub-retinal fluid (SRF) accumulation or recurrences leading to continuous visual impairment [4]. The vascular leakage of chronic CSC results from the dysfunction of the retinal pigment epithelium (RPE) outer blood-retinal barrier, most likely caused by choroidal vasodilatation and hyperpermeability [5, 6]. Bullous retinal detachment, which can eventually lead to vision loss as a result of irreversible retinal damage, is an extremely rare manifestation of CSC. However, the precise pathogenesis of why only a small subset of eyes with CSC are complicated by bullous retinal detachment has remained unclear until now. In recent decades, the relationship between CSC and corticoid has been one of the

\textsuperscript{1} Department of Ophthalmology, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People’s Hospital, Peking University Health Science Center, Xizhimen South Street 11, Xi Cheng District, Beijing 100044, China

\textsuperscript{2} Department of Ophthalmology, 3rd People’s Hospital of Linyi, Linyi, China

\textsuperscript{*} Mingwei Zhao
zhaomingwei64@163.com
most intriguing aspects of the disease. A previous study reported that glucocorticoids can reduce macular edema and aggravate SRF accumulation in CSC patients [6]. Additionally, in previous reports, the occurrence of bullous retinal detachment was also associated with a history of glucocorticoids [7, 8].

Based on the currently available literature, the traditional treatment of CSC consists of photodynamic therapy (PDT) and laser photocoagulation. However, there are limited clinical data on the therapy of patients with bullous retinal detachment thus far. In the present study, we present a series of cases of bullous retinal detachment that responded favorably to half-dose PDT without any additional complications during the follow-up period of more than 6 months.

Methods

Patients

Six eyes of six patients with bullous retinal detachment secondary to CSC were included in this prospective study. The diagnosis of bullous retinal detachment was established by ophthalmoscopy, ophthalmic B scan, fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and indocyanine green angiography (ICGA). Bullous retinal detachment was designed as a neurosensory detachment (more than 10 disc diameters) with shifting SRF attributed to a leak or leaks at the level of the RPE with a bullous appearance that extended to the inferior vascular arcades [9]. All of the following had to be present to diagnose bullous retinal detachment: exudative retinopathy observed by fundoscopy, retinal detachment observed by B scan, SRF observed by OCT, vascular leakage observed by FFA, and corresponding hyperfluorescence observed by ICGA. The patients were consecutively enrolled from July 2015 to May 2017 in Peking University People’s Hospital. The patients recruited received PDT without other kind of treatments. The study protocol was approved by the Ethical Committee and Institutional Review Board of Peking University People’s Hospital (Beijing, China) and was in accordance with the Declaration of Helsinki. Written informed consent was obtained from the recruited bullous retinal detachment patients prior to PDT.

Photodynamic therapy treatment and follow-up

Half-dose intravenous (3 mg/m²) verteporfin was infused over a period of 10 min. A contact glass was positioned on the affected eye, followed by delivery of 689 nm laser energy to the target zone 15 min after infusion. Abnormal vascular areas selected based on hyperfluorescent zones observed by ICGA of the mid-phase, corresponding to hyperfluorescent leakage on FFA of the mid-phase were treated. For PDT, the spot sizes were chosen according to abnormal vascular areas and a total light energy of 50 J/cm² for 83 s was used. Separate areas of choroidal hyperpermeability were treated separately. If SRF was not reduced until the second month after PDT, then the eye received another half-dose PDT. The patients were instructed to avoid light for 48 h after PDT. BCVA, ophthalmoscopy, ophthalmic B scan, FFA, OCT, and ICGA results were examined upon follow-up at 1, 3, and 6 months after treatment.

Statistical analyses

For statistical analyses, a paired-samples t test was used in SPSS Statistics (version 20; IBM) to compare logMAR BCVA during each visit at baseline and 1, 3, and 6 months after PDT. The level of statistical significance was set at p < 0.05.

Results

This study included six eyes from six consecutive patients. Table 1 summarizes the clinical characteristics of six patients with bullous retinal detachment. The patients were five males and one female with an average age of 40.5 ± 6.7 years (mean ± standard deviation). The disease affected a single eye in all six patients (100%). Regarding medical history, two patients (33.3%) had bullous retinal detachment associated with systemic corticosteroid therapy for initial nephritic syndrome and intravitreal injection of triamcinolone acetonide (TA) for misdiagnosis of uveitis. Four patients (66.7%) presented with characteristics of classic CSC initially, followed by development of bullous retinal detachment 3 months to 10 years later. Except for one patient who lost vision in the fellow eye because of glaucoma at a young age, the remaining five patients had classic CSC in the fellow eyes.

Bullous retinal detachment was invariable in the posterior pole and peripheral retina, characterized by accumulation of SRF shifting on different positions. Retinal detachment and macular SRF were observed in six eyes (100%). Peripheral hyperfluorescent foci were observed by FFA in five eyes (83.3%). Sub-retinal fibrin occurred in three eyes (50%) as observed by OCT. Two eyes (33.3%) were identified with retinal folds.

All six eyes received ICGA-guided half-dose verteporfin PDT. The mean number of PDT spots was 2.83 ± 1.47 (range from 1 to 5) with a mean spot size of 4647 ± 996 μm in diameter (range from 3000 to 6000 μm). Three months after PDT, retinal reattachment on B scan and resolution of sub-retinal fluid (SRF) on an OCT image were observed in five eyes. There was no significant difference in the mean logMAR BCVA between the baseline and 1 month after PDT (P = 0.477). At 3 months after PDT, the mean logMAR
BCVA improved significantly from a baseline value of 1.02 to 0.54 ($P = 0.044$). At 6 months after PDT, the mean logMAR BCVA further improved to 0.46 ($P = 0.025$) and remained stable. The changes in BCVA of the five eyes at different time points are shown in Fig. 1. One affected eye (16.7%) received a second half-dose PDT, as SRF was not reduced until the second month after the first therapy. Next, we adjusted the therapeutic areas of PDT based on ICGA imaging. Retinal reattachment was observed 1 month after the second therapy, and SRF resolution was observed 3 months after the second therapy. BCVA improved from a baseline value of 20/63 to 20/20 1 month after the second PDT and remained stable until the 6th month after the second PDT.

No major sequelae for PDT, such as persistent choroidal ischemia, macular hemorrhage, or severe chorioretinal degeneration, were observed in any eyes during the follow-up periods. During the follow-up more than 6 months, no recurrence occurred.

**Case reports**

**Case 1**

A 35-year-old woman presented with blurred vision and photopsia in both eyes for 3 months. Her BCVA was 20/63 OU (in each eye). Ophthalmoscopy and ophthalmic B scan of the right eye revealed bullous retinal detachment in the posterior pole (Fig. 2a, b). The patient was treated with oral prednisone at 30 mg per day for over 6 years for nephritic syndrome. FFA of the right eye revealed hyperfluorescent leakage in areas corresponding to exudative retinal detachment (Fig. 2c). OCT of the right eye disclosed neuro-retinal detachment (Fig. 2d). The left eye had focal retinal pigment epithelial detachment in the inferior retina. The right eye received a 50% dose of verteporfin PDT with a spot size of 5000 $\mu$m over the abnormal vascular area in indocyanine green angiography (Fig. 2e). One month later, the SRF was partly reduced (Fig. 2f, g), while 3 months later, there was retinal reattachment, and the complete absence of SRF was confirmed by ophthalmic B scan and OCT (Fig. 2h, i). At the 6-month examination after photodynamic therapy, the BCVA improved to 20/50 in the right eye, and a mottled appearance was observed in the fundus (Fig. 2j). FFA showed a mottled shape upon fluorescence transmission, and no fluorescein leakage was observed (Fig. 2k). ICGA showed hypofluorescence in the lesion area (Fig. 2l).

**Case 2**

A 35-year-old man first noted visual loss in both eyes and was diagnosed with classic central serous chorioretinopathy; he received argon laser photocoagulation in the right eye at another hospital. Two years later at the age of 37, the patient
experienced severe blurring in the left eye, with a BCVA of 20/80 in the right eye and 20/200 in the left eye. Ophthalmoscopy of the left eye disclosed exudative lesions in the macula and inferotemporal retina (Fig. 3a), which were confirmed as bullous retinal detachment by ophthalmic B scan (Fig. 3b). FFA revealed hyperfluorescent leakage in areas of exudative retinal detachment (Fig. 3c). OCT disclosed SRF, sub-retinal fibrin adjacent, and retinal folds in the lesion area (Fig. 3d). His left eye received a 50% dose of verteporfin PDT with two spots of 6000 and 3000 μm under the guidance of ICGA (Fig. 3e). One month after PDT, the SRF obviously decreased and sub-retinal fibrin disappeared based on ophthalmic B scan and OCT (Fig. 3f, g). Three months later, ophthalmoscopy and ophthalmic B scan showed that the exudative retinal detachment was resolved completely at the macula (Fig. 3h, i). FFA revealed a mottled appearance of transmitted light in the posterior pole (Fig. 3j). OCT image demonstrating a mottled shape in fluorescence transmission and no fluorescein leakage 6 months after PDT (Fig. 3k).
fluorescence and no hyperfluorescent leakage (Fig. 3j), and OCT showed the complete resolution of SRF and the disappearance of retinal folds (Fig. 3k). ICGA also disclosed the disappearance of hyperfluorescent leakage and the mottled appearance that remained (Fig. 3l). At the 6-month examination, his BCVA improved to 20/40 in the left eye and remained stable.

Case 3

A 38-year-old man with a history of blurred vision in the right eye for 1 year was diagnosed with CSC in the left eye, which was treated with argon laser photocoagulation 10 years ago. His BCVA was 20/63 in the right eye and 20/200 in the left eye. Ophthalmoscopy of the right eye revealed retinal detachment accompanied with yellowish, fibrinoid exudative lesions in the temporal macula (Fig. 4a). Ophthalmic B scan confirmed bullous retinal detachment in the right eye (Fig. 4b). FFA disclosed multiple intense sub-retinal leakage in areas corresponding to exudative lesion and in the superior retina (Fig. 4c). OCT disclosed large amounts of SRF in the macular and temporal retinal areas (Fig. 4d). His right eye received a 50% dose of verteporfin PDT with three spots under the guidance of ICGA (Fig. 4e). Ophthalmic B scan disclosed obviously reduced bullous retinal detachment 1 month after PDT (Fig. 4f), and his BCVA improved to 20/25. However, the SRF slowly resolved. Although the OCT image revealed a reduction in sub-retinal fibrin, the SRF remained and resolved slowly until the second month after PDT (Fig. 4g). Considering the slow resolution of SRF, the patient received a second 50% dose of verteporfin PDT in the right eye. We adjusted the therapeutic area with a spot size of 5000 μm under the guidance of ICGA. One month after the second PDT (3 months after the first PDT), ophthalmoscopy of the right eye revealed the disappearance of the yellowish, fibrinoid exudative lesions (Fig. 4h). Additionally, the reattached retina was observed on B scan, and SRF in the temporal area markedly decreased in the OCT image (Fig. 4i, j). OCT revealed nearly resolved SRF 2 months after the second PDT (Fig. 4k), and the SRF was completely resolved 3 months after...
the second PDT (Fig. 4l). The patient’s BCVA of the right eye improved to 20/20 in the third month after the second PDT and remained stable until the sixth month after the second PDT. No recurrence occurred during the follow-up of more than 6 months after the second PDT.

Case 4

A 48-year-old man presented with blurred vision in the left eye for 2 weeks. He had a history of intravitreal injection of triamcinolone acetonide (TA) for a misdiagnosis of uveitis in the left eye 1 month prior to examination. Additionally, his left eye was treated with two periocular injections of dexamethasone, one intravitreal injection of conbercept and one application of laser photocoagulation within 1 month at another hospital. However, there was with no improvement of visual acuity. His BCVA was 20/20 in the right eye and 20/200 in the left when he came to our outpatient facility. Ophthalmoscopy of the left eye disclosed intraocular TA in the nasal retina and non-rhegmatogenous retinal detachment with multifocal exudative lesions in the posterior pole (Fig. 5a). An ophthalmic B scan revealed retinal detachment in the left eye (Fig. 5b). FFA showed multiple hyperfluorescent leakage in areas corresponding to exudative retinal detachment at baseline (Fig. 5c). OCT disclosed SRF at the area of macula and temporal retina (Fig. 5d). His left eye received a 50% dose of verteporfin PDT with two spots of 5000 μm and one spot of 3000 μm under the guidance of ICGA (Fig. 5e). One month later, an ophthalmic B scan revealed obviously reduced bulbus retinal detachment, and OCT disclosed the decreased SRF (Fig. 5f, g). Three months after PDT, ophthalmoscopy and an ophthalmic B scan revealed the completely resolved exudative retinal detachment (Fig. 5h, i). FFA showed hypoﬂuorescence, and ICGA revealed hypoﬂuorescence in the lesion area (Fig. 5j, k). SRF on the OCT image disappeared, and the macula regained normal anatomic structure (Fig. 5l). At the 6-month examination, his vision acuity improved to 20/100 in the left eye, and no recurrence occurred.

Case 5

A 50-year-old man presented with blurred vision in the right eye for a year. His BCVA was 20/200 in the right eye, while the left eye worsened to no light perception because of glaucoma at an early age. Ophthalmoscopy of
the right eye disclosed non-rhegmatogenous retinal detachment in the posterior pole, and ophthalmic B scan confirmed the bullous retinal detachment (Fig. 6a, b). FFA revealed several hyperfluorescent leakages around the optic disc corresponding to exudative detachments (Fig. 6c). OCT of the right eye disclosed exudative retinal detachment with serious SRF, sub-retinal fibrin, and retinal folds (Fig. 6d). Five spots of 50% dose of verteporfin PDT were administered under the guidance of ICGA (Fig. 6e). One month after PDT, an ophthalmic B scan revealed obviously reduced bullous retinal detachment (Fig. 6f). SRF and sub-retinal fibrin decreased and the retinal folds disappeared from the OCT image (Fig. 6g). Three months after PDT, ophthalmoscopy and an ophthalmic B scan revealed that the bullous retinal detachment was completely resolved (Fig. 6h, i). A mottled shape was observed by fluorescence transmission, and no fluorescein leakage was found in the FFA image (Fig. 6j). OCT showed normal macula structure in the right eye (Fig. 6k). ICGA disclosed hypofluorescence in the lesion area (Fig. 6l). His BCVA improved to 20/40, with no recurrence during the follow-up of more than 6 months.

Case 6

A 35-year-old man presented with blurred vision in the left eye for near 3 months. His BCVA was 20/25 in the right eye and 20/800 in the left eye. Ophthalmoscopy of the left eye revealed retinal detachment in the inferior retina (Fig. 7a). An ophthalmic B scan confirmed bullous retinal detachment in the left eye (Fig. 7b). FFA disclosed multiple hyperfluorescent leakages in areas of temporal retina and hypofluorescent exudative retinal lesions corresponding to retinal detachment in the inferior retina (Fig. 7c). OCT disclosed large amounts of SRF (Fig. 7d). His left eye received a 50% dose of verteporfin PDT with two spots of 5000 μm under the guidance of ICGA (Fig. 7e). One month after PDT, the SRF was partly resolved based on an ophthalmic B scan and OCT (Fig. 7f, g). Three months after PDT, SRF was completely resolved, as confirmed by ophthalmic B scan, OCT, and opthalmoscopy (Fig. 7h–j). At the 6-month examination after photodynamic therapy, his BCVA improved to 20/80 in the left eye. An FFA image showed a mottled shape in fluorescence transmission, and no fluorescein leakage was found.
An ICGA image showed the disappearance of hyperfluorescence leakage in the lesion area (Fig. 7k). In fact, the treatment for bullous retinal detachment has not been well established. In past decades, laser photocoagulation was the traditional treatment for extrafoveal leakage area [15]. The rapid resolution of bullous retinal detachment was reported after photocoagulation of the areas of RPE detachment [16]. However, there have been only a limited number of case reports on the use of PDT for bullous retinal detachment [17, 18].

In this study, we evaluated the efficacy of half-dose verteporfin PDT with multifocal and large laser spots in the treatment of bullous retinal detachment. Although PDT is generally considered a common therapy for classic CSC [10], it has not been popularized among the treatment of bullous retinal detachment, a severe variant of CSC.

Besides PDT, studies suggested that laser photocoagulation may be of benefit in reducing SRF and oral administration of mineralocorticoid receptor antagonist eplerenone or intravitreal antiangiogenic drugs may be helpful to improve visual acuity [11, 12]. Some cases also indicated that transpupillary thermotherapy seemed to be effective for the treatment of bullous variant of CSC in the short term and internal drainage could lead to anatomical and functional improvement [13, 14].

In 1973, Gass first reported a group of patients with bullous exudative detachment [19]. Bullous retinal detachment is a rare sub-type of CSC characterized by multifocal posterior exudations with shifting SRF [20]. CSC is a common maculopathy mainly affecting working-age populations and is observed more frequently in men than in women [21]. In a previous study, Balaratnasingam et al. [9] reported a group of bullous retinal detachment patients with a mean age of 53.8 years, and 50% of patients were bilaterally affected, while Otsuka et al. [22] reported 25 patients—21 men and 4 women—with a mean age at disease onset of 43.1 years. Our study showed that the mean age was 40.5 ± 6.7 years and the
male-to-female ratio was 5:1, which was similar to previous reports. However, the disease affected a single eye in all six patients, accounting for 100% in our group, which was different from the results of previous studies [9, 23].

Previous studies have shown an association between retinal disease and retinal or cardiac transplantation with the bullous variant of CSC [24, 25]. Corticosteroids also have been implicated in the pathogenesis of bullous retinal detachment [7, 26]. Balaratnasingam et al. [9] reported that 50% of patients had corticosteroid use in the bullous retinal detachment group. In the present study, two patients, accounting for 33.3%, had undergone corticosteroid therapy: one (patient 1) for initial disease of nephritic syndrome and the other (patient 4) for intravitreal injection of TA. The latter patient was initially misdiagnosed with uveitis by another ophthalmologist and was subsequently administered various treatments, including corticosteroids, prior to visiting our hospital. Although CSC is a self-limiting condition in the majority of patients, the recognition of this atypical form is important. Failure to differentiate this condition from inflammatory disease may result in the inappropriate use of corticosteroids, leading to disease progression and visual loss. This disease can also occur spontaneously without any history of corticosteroid use. The remaining four patients, accounting for 66.7% in the present case series, initially presented with characteristics of classic CSC, followed by the development of bullous retinal detachment 3 months to 10 years later. A previous study reported that patients with classic CSC developed the severe variant after 7 months to 9 years [20]. A patient in the present study progressed to bullous retinal detachment in the shortest time of 3 months from the stage of acute CSC, which, to our knowledge, has seldom been reported. The new findings in the present study will aid the exploration of the pathophysiology of bullous retinal detachment. We suggest that bullous retinal detachment is not a single pathogenic risk factor but may be a result of interactions between environmental, genetic, and individual conditions.

Peripheral hyperfluorescent foci were observed on FFA in 83.3% of eyes in the present study. We also observed sub-retinal fibrin on OCT in 50% of affected eyes. Hooymans [27] reported fibrotic scar formation in the development of CSC to severe variants of bullous retinal...
detachment during systematic treatment with corticosteroids. Balaratnasingam et al. described a more frequent occurrence of sub-retinal fibrin in the eyes of the bullous CSC group than in the eyes of the non-bullous CSC group [9]. Retinal folds were observed in 33.3% of eyes with bullous retinal detachment in the present case series. We inferred the folds were association with retinal edema and choroidal vasodilatation.

In the present case series, all affected eyes received half-dose PDT, including five eyes that received single PDT, accounting for 83.3%, and one eye that received a second PDT, accounting for 16.7%. The second PDT was administered when SRF accumulation was not reduced until 2 months after the first therapy. After adjustment of the therapeutic area guided by ICGA, retinal reattachment was acquired 1 month later. Studies have shown that vascular damage and cytotoxicity associated with PDT are dosage-dependent [28]. Considering the dosage-dependent administration of verteporfin and the results of a previous study on the efficacy of PDT in the treatment of CSC, we used half-dose PDT in the present study [29]. The PDT treatment was guided by ICGA, which has become the mainstream procedure to guide PDT to target hyperfluorescent areas in mid-phase [30, 31]. The entire area of abnormal choroidal vessels could be covered by ICGA-guided PDT to prevent further leakage. The spot sizes in the present study ranged from 3000 to 6000 μm with a mean size of 4647 ± 996 μm in diameter.

The success rate of half-dose PDT in the present study was defined as the reattachment of retina on ophthalmology B scan. These data showed a success rate of 100% after PDT treatment for bullous retinal detachment, with an absence of SRF on OCT. The recurrence rate was as low as zero during the follow-up of more than 6 months. Remarkably, the visual results were significantly improved 3 and 6 months after half-dose PDT compared to the baseline. Similar results in case series of bullous retinal detachment have not previously been reported. The present study provides clinical evidence for the treatment of bullous retinal detachment with PDT.

Since the present sample size was small and the follow-up time was short, a prospective randomized control study involving a large number of patients with long-term follow-up is needed for further investigation of the advantage of PDT.

In conclusion, this study has demonstrated the effective treatment of half-dose PDT with multifocal and large laser spots in bullous retinal detachment, leading to significant visual and anatomic improvement in all affected eyes in the present case series. We are currently performing a multicenter prospective randomized controlled trial to explore the efficacy of PDT for bullous retinal detachment.

**Funding** Beijing Municipal Science and Technology Commission provided financial support in the form of Science and Technology Program of Beijing (No. Z171100002217081, Z161100000516037). National Natural Science Foundation of China provided financial support in the form of National Natural Science Foundation of China (Grant NO. 81470651, 81770943). This work was supported by National key research and development program (2016YFC0904801, 2017YFC0111204). The sponsor had no role in the design or conduct of this research.

**Compliance with ethical standards**

**Conflict of interest** All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Liew G, Quin G, Gillies M et al (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214
2. Quin G, Liew G, Ho IV et al (2013) Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 41:187–200
3. Gergely R, Kovács L, Schneider M et al (2017) Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 37:1084–1091
4. Ross A, Ross AH, Mohamed Q (2011) Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 22:166–173
5. van Dijk EHC, Dijkman G, Boon CJF (2017) Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. Graefes Arch Clin Exp Ophthalmol 255:2029–2035
6. Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118
7. Gao X, Li X (2011) Development of bullous retinal detachment during systematic corticosteroid treatment. Graefes Arch Clin Exp Ophthalmol 249:1905–1907
8. Cebeci Z, Oray M, Bayraktar S et al (2017) Atypical central serous chorioretinopathy. Turk J Ophthalmol 47:238–242
9. Balaramanasingam C, Freund KB, Tan AM et al (2016) Bullous variant of central serous chorioretinopathy: expansion of phenotypic features using multimethod imaging. Ophthalmology 123:1541–1552
10. Tsng CC, Chen SN (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99:1070–1077
11. Nicholson B, Noble J, Forooaghian F et al (2014) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126
12. Çakir B, Fischer F, Ehiken C et al (2016) Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:2151–2157
13. John VJ, Mandelcorn ED, Albini TA (2014) Internal drainage for chronic macula-involving serous retinal detachment in idiopathic central serous chorioretinopathy. Int Ophthalmol 34:91–95
14. Kawamura R, Ideta H, Hori H et al (2012) Transpupillary thermotherapy for atypical central serous chorioretinopathy. Clin Ophthalmol 6:175–179
15. Robertson DM (1986) Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology 93:972–974
16. Chen JC, Lee LR (2005) Central serous chorioretinopathy and bullous retinal detachment: a rare association. Clin Exp Ophthalmol 33:248–252
17. Kuroyanagi K, Sakai T, Kasa K, Tsuneoka H (2013) Spectral domain optical coherence tomography and angiographic findings in multifocal posterior pigment epitheliopathy treated with low-fluence photodynamic therapy. Clin Exp Ophthalmol 41:126–129
18. Ng WW, Wu ZH, Lai TY (2011) Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. J Med Case Rep 5:208
19. Gass JD (1973) Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol 75:810–812
20. Otsuka S, Ohba N, Nakao K (2002) A long-term follow up study of severe variant of central serous chorioretinopathy. Retina 22:25–32
21. Tsai DC, Chen SJ, Huang CC et al (2013) Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One 8:e66858
22. Otsuka S, Ohba N, Nakao K (2002) A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina 22:25–32
23. Sahu DK, Namperumalsamy P, Hilton GF, de Sousa NF (2000) Bullous variant of idiopathic central serous chorioretinopathy. Br J Ophthalmol 84:485–492
24. Gass JD (1992) Bullous retinal detachment and multiple retinal pigment epithelial detachments in patients receiving hemodialysis. Graefes Arch Clin Exp Ophthalmol 230:454–458
25. Fawzi AA, Holland GN, Kreiger AE et al (2006) Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 113:805–813
26. Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747
27. Hooymans JM (1998) Fibrotic scar formation in central serous chorioretinopathy developed during systematic treatment with corticosteroids. Graefes Arch Clin Exp Ophthalmol 236:876–879
28. Schlötzer-Schrehardt U, Viestenz A, Naumann GO et al (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757
29. Zhao M, Zhang F, Chen Y et al (2015) A 50% versus 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol 133:333–340
30. Breukink MB, Mohr JK, Ossewaarde-van Norel A et al (2016) Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol 94:187–197
31. Rouvas A, Nikita E, Chatziralli I et al (2015) Long-term follow-up of standard photodynamic therapy with standardized small spot size for diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 25:229–234